Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Change in Acquisitions & Divestments: 2021-2025

Historic Change in Acquisitions & Divestments for Janux Therapeutics (JANX) over the last 4 years, with Sep 2025 value amounting to $126.4 million.

  • Janux Therapeutics' Change in Acquisitions & Divestments rose 179.79% to $126.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $310.4 million, marking a year-over-year increase of 55.44%. This contributed to the annual value of $212.9 million for FY2024, which is 23.41% down from last year.
  • Janux Therapeutics' Change in Acquisitions & Divestments amounted to $126.4 million in Q3 2025, which was up 33.41% from $94.7 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Change in Acquisitions & Divestments ranged from a high of $126.4 million in Q3 2025 and a low of $22.1 million during Q3 2021.
  • Its 3-year average for Change in Acquisitions & Divestments is $67.6 million, with a median of $63.2 million in 2023.
  • Per our database at Business Quant, Janux Therapeutics' Change in Acquisitions & Divestments spiked by 427.21% in 2022 and then crashed by 52.89% in 2024.
  • Janux Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $112.0 million in 2021, then declined by 22.77% to $86.5 million in 2022, then crashed by 48.27% to $44.8 million in 2023, then rose by 29.61% to $58.0 million in 2024, then skyrocketed by 179.79% to $126.4 million in 2025.
  • Its Change in Acquisitions & Divestments was $126.4 million in Q3 2025, compared to $94.7 million in Q2 2025 and $31.3 million in Q1 2025.